TY-JUR T1 - PORPOPILMONI高血压中的MACITENTAN（POPH）：来自OPUS和ORPHEUS JF的真实数据 - 欧洲呼吸期刊JO - EUR RESPIR J DO - 10.1183 / 13993003.Congress-2019.Pa5457 VL - 54 IS - Spect 63 SP- PA5457 Au - Kim，Nick Au - Chin，Kelly Au - McLaughlin，Vallerie Au - Rictrepo-Jaramillo，Ricardo Au - Safdar，Zeenat Au - 品牌，Monika Au - Flynn，Megan Au - Leroy，Sandrine Au - Morganti，Adele Au- Channick，Richard Y1 - 2019/09/09/28 UR - //www.qdcxjkg.com/content/54/suppl_63/pa5457.abstract n2 - 简介：opsumit®用户（opus）注册表和opsumit®历史用户队列（Orpheus）捕获Macitentan治疗的肺动脉高压（PH）患者（PT）（PT）（PTS）的真实体验，包括Poph.aims和目标：描述在Opus / Orpheus的Macitentan新治疗的Poph Pts中的特征和安全性。Opus是一项潜在，多期，长期，观测的药物登记处（自2014年4月以来正在进行; NCT02126943）。Orpheus是一项回顾性的多方面医学图表评论（2013年10月 - 2017年3月; NCT03197688）。肝功能试验（LFT）升高也为特发性/遗传（IPAH / HPAH）PTS提供了升级。结果：到2018年10月，Opus / Orpheus具有170个具有后续数据的Poph Pts。在Macitentan启动时，中位数（Q1，Q3）年龄为58（52,63）岁;65分，录制的录制职业阶级（FC），34（52.3％）为FC III / IV;115（67.6％）PTS接受其他肺动脉高压治疗。 Median (Q1, Q3) exposure to macitentan was 12 (2.8, 26.0) months; 63 (37.1%) pts discontinued treatment; 34 (20.0%) due to an adverse event (AE), 3 (1.8%) due to a hepatic AE (HAE) and 26 (15.3%) for other reasons. LFT data are shown in the table. The 12-month Kaplan-Meier survival estimate was 87% (95% CI, 80, 92).Conclusions: As expected, LFT abnormalities were observed in this vulnerable population. HAEs accounted for a small number of discontinuations.View this table:FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA5457.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -